25TH IABCR CONGRESS CONFERENCE: PERSONALIZED BREAST CANCER THERAPY

描述（由申请人提供）：本次会议是国际乳腺癌研究协会第25届大会，旨在促进小鼠模型的开发和使用，以测试用于治疗和治愈人类乳腺癌的药物和创新生物学策略。 会议将为业界和学术界备受尊敬的国家和国际领导人提供一个论坛。 该会议旨在建立必要的联系，以促进科学家和工业界之间的后续合作，并鼓励使用这些模型来减轻人类疾病。 这次会议有望预示着行业，临床医生和科学家之间合作的新时代，他们通过将这些团体聚集在一起进行有意义的会议和讨论来开发模型。 它将回顾各个科学学科的进展，并使参与者接触到新方法和新模型，这些方法和模型可能比以前的小鼠研究预期的应用范围更广。 它还将展示该领域如何利用敏感的体内成像技术进入新的有前途的治疗干预领域。 这次会议将专门讨论乳腺癌研究中的几个新兴领域。 在Dennis Slamon博士的主题演讲之后，第一次会议将讨论乳腺癌的病理学和分子特征。 本次会议还将包括乳腺癌遗传学领域公认的领导者乔·格雷博士的全体演讲。 第二部分将讨论乳腺癌中激活的各种信号转导途径及其作为治疗靶点的潜在效用。第三次会议将集中在生长因子和激素受体在乳腺癌的发生和发展中的作用。 本次会议还将包括一个全体讲座博士肯特奥斯本处理的概念之间的串扰生长因子受体和激素。 第三部分将涉及肿瘤微环境和癌症干细胞在乳腺癌发展中的新兴作用。 本次会议将包括约翰·康迪利斯博士的全体演讲，涉及炎症反应在调节乳腺癌进展中的作用。 会议的最后一次会议将讨论用于治疗乳腺癌的新兴疗法。 来自学术和制药和生物技术领域的发言者将有突出的代表。 会议还将包括A Ullrich博士的全体演讲，他开创了靶向HER2癌基因治疗乳腺癌的概念。

DESCRIPTION (provided by applicant): This meeting, the 25th Congress of the International Association for Breast Cancer Research, is designed to foster the development and use of mouse models for testing pharmaceuticals and innovative biological strategies for the treatment and cure of human breast cancer. The meeting will provide a forum for highly regarded national and international leaders in industry and academia. The meeting is designed to establish the contacts necessary to foster subsequent collaborations between scientists and industry and to stimulate the use of the models to alleviate human disease. The meeting promises to herald a new era of cooperation between industry, clinicians, and scientists who develop the models by bringing the groups together for meaningful meetings and discussions. It will review the progress in the various scientific disciplines and expose the participants to new approaches and new models that might serve much wider applications than has been expected from previous murine studies. It will also show how the field is moving into new promising areas of therapeutic interventions, taking advantage of sensitive in vivo imaging techniques. This meeting will specifically address several emerging areas in breast cancer research. Following a keynote lecture from Dr. Dennis Slamon, the first session will deal with the pathology and molecular profiling of breast cancer. This session will also include a plenary lecture from Dr. Joe Gray; an acknowledged leader in area of breast cancer genetics. The second session will deal with various signal transduction pathways activated in breast cancer and their potential utility as therapeutic targets. The third session will focus on the role of growth factor and hormone receptors in the initiation and progression of breast cancer. This session will also include a plenary lecture from Dr. Kent Osborne dealing with the concept of crosstalk between both growth factor receptors and hormones. The third session will involve the emerging roles of tumor microenvironment and cancer stem cell in development of breast cancer. This session will include a plenary lecture from Dr. John Condeelis dealing with the role of inflammatory response in regulating breast cancer progression. The final session of the meeting will deal with the emerging therapies that are used in the treatment of breast cancer. Speakers from both academic and pharmaceutical and biotechnology fields will be prominently represented. The session will also include a plenary lecture from Dr. A Ullrich who pioneered the concept of targeting the HER2 oncogene in the treatment of breast cancer.